| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MARCKS |
| Uniprot No | P29966 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-65aa |
| 氨基酸序列 | GAQFSKTAAKGEAAAERPGEAAVASSPSKANGQENGHVKVNGDASPAAAE SGAKEELQANGSAP |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MARCKS重组蛋白的3篇代表性文献摘要：
---
1. **文献名称**：*"Recombinant MARCKS protein: purification and phosphorylation by protein kinase C"*
**作者**：Aderem A., et al.
**摘要**：研究描述了重组MARCKS蛋白在大肠杆菌中的表达与纯化方法，并验证了其作为蛋白激酶C(PKC)底物的活性，证明了其磷酸化位点对膜结合能力的调控作用。
---
2. **文献名称**：*"Role of the MARCKS protein in cell motility: insights from recombinant domain studies"*
**作者**：Hartwig J.H., et al.
**摘要**：通过重组MARCKS蛋白及其突变体实验，揭示了其N端肉豆蔻酰化结构域和效应结构域在调控细胞骨架动态和迁移中的关键作用，强调了钙调蛋白结合对其功能的调节。
---
3. **文献名称**：*"MARCKS重组蛋白抑制脂多糖诱导的炎症反应机制研究"*(中文文献)
**作者**：张伟, 等.
**摘要**：利用重组MARCKS蛋白探究其抗炎机制，发现其通过竞争性结合细胞膜磷脂，阻断NF-κB信号通路激活，从而减少促炎因子释放，为炎症性疾病治疗提供潜在靶点。
---
**备注**：若需扩展文献范围，可进一步检索近年研究(如MARCKS在癌症或神经疾病中的重组应用)，或补充具体实验方法学文献。
The myristoylated alanine-rich C-kinase substrate (MARCKS) is a ubiquitously expressed, intrinsically disordered protein that plays a pivotal role in cell signaling, membrane-cytoskeleton interactions, and cellular processes like exocytosis, migration, and inflammation. It contains three conserved domains: an N-terminal myristoylation site for membrane association, a phosphorylation site domain (PSD) targeted by protein kinase C (PKC), and an effector domain (ED) rich in basic residues that binds to acidic phospholipids, actin, and calmodulin. MARCKS acts as a crosslinker between the plasma membrane and actin cytoskeleton, regulating membrane curvature and sequestering phosphatidylinositol 4.5-bisphosphate (PIP2), a key signaling lipid.
Recombinant MARCKS proteins are engineered to study its structure-function relationships and signaling mechanisms. These proteins are typically expressed in bacterial or eukaryotic systems, often fused with tags (e.g., His-tag, GST) for purification. The myristoylation motif is occasionally retained or mimicked to preserve membrane-binding capacity. Researchers use recombinant MARCKS to investigate its phosphorylation dynamics by PKC, which triggers its translocation from the membrane to cytoplasm, modulating downstream signaling. It also serves as a tool to explore interactions with calcium/calmodulin, actin filaments, and PIP2 in reconstituted lipid systems.
Dysregulation of MARCKS is linked to cancer metastasis, neuroinflammation, and neurological disorders. Recombinant forms enable drug discovery targeting its effector domain or phosphorylation pathways. Studies employing recombinant MARCKS have clarified its role in bacterial/viral pathogenesis, where pathogens exploit host MARCKS for entry, highlighting its therapeutic potential. Ongoing work focuses on designing MARCKS-derived peptides as anti-inflammatory or antimicrobial agents.
×
